Novel nonpharmacologic approaches for stroke prevention in atrial fibrillation: results from clinical trials

Riccardo Proietti1,2
Jacqueline Joza1
Andrea Arensi2
Michael Levi1
Vincenzo Russo3
Apostolos Tzikas4
Paolo Danna2
Antonio Sagone2
Maurizio Viecca2
Vidal Essebag1,5

1McGill University Health Center, Montreal, QC, Canada; 2Cardiology Department, Luigi Sacco Hospital, Milano, Italy; 3Cardiology Department, Second University of Naples, Monaldi Hospital, Naples, Italy; 4Interbalkan European Medical Centre, Thessaloniki, Greece; 5Hôpital Sacré-Coeur de Montréal, Montreal, QC, Canada

Abstract: Atrial fibrillation (AF), the most common cardiac arrhythmia, confers a 5-fold risk of stroke that increases to 17-fold when associated with mitral stenosis. At this time, the most effective long-term solution to protect patients from stroke and thromboembolism is oral anticoagulation, either with vitamin K antagonists (VKAs) or a novel oral anticoagulant (NOAC). Despite the significant benefits they confer, both VKAs and NOACs are underused because of their increased potential for bleeding, and VKAs are underused because of their narrow therapeutic range, need for regular international normalized ratio checks, and interactions with food or medications. In patients with nonvalvular AF, approximately 90% of strokes originate from the left atrial appendage (LAA); in patients with rheumatic mitral valve disease, many patients (60%) have strokes that originate from the left atrium itself. Surgical LAA amputation or closure, although widely used to reduce stroke risk in association with cardiac surgery, is not currently performed as a stand-alone operation for stroke risk reduction because of its invasiveness. Percutaneous LAA closure, as an alternative to anticoagulation, has been increasingly used during the last decade in an effort to reduce stroke risk in nonvalvular AF. Several devices have been introduced during this time, of which one has demonstrated noninferiority compared with warfarin in a randomized controlled trial. This review describes the available technologies for percutaneous LAA closure, as well as a summary of the published trials concerning their safety and efficacy in reducing stroke risk in AF.

Keywords: left atrial appendage closure, atrial fibrillation, CHADS

Introduction

Atrial fibrillation (AF) is the most common cardiac arrhythmia, affecting 1%–2% of the general population, although this may be an underestimate. Studies assessing silent AF using modern implantable rhythm monitoring devices suggest that up to 50%–60% of patients older than 65 years may have unsuspected episodes of AF.1,2 The relevance of these data is best understood in view of the increased mortality and morbidity associated with AF: nonvalvular AF confers a fivefold risk of stroke,1 which increases to 17-fold in patients with mitral stenosis.3

At the present time, vitamin K antagonists (VKAs) remain the mainstay for stroke prevention in AF. In a meta-analysis by Hart et al,4 a 64% reduction in overall stroke risk was observed in patients using adjusted-dose VKAs (the reduction increased to 68% when only ischemic strokes were considered). Despite such strong evidence, warfarin is still underused because of its associated bleeding risk, need for regular monitoring, narrow therapeutic range, and common interactions with other medications as well as food.4,5 In certain subgroups of patients, or when bleeding risk is elevated,
acetylsalicylic acid (ASA), alone or in combination with clopidogrel, may be considered as an alternative to VKAs. However, antiplatelet agents are inferior to VKAs for stroke prevention and may be associated with similar bleeding risk, particularly in elderly patients.

As an alternative to VKAs, novel oral anticoagulant agents (NOACs) have been increasingly used. The RE-LY (Randomized Evaluation of Long-term Anticoagulant Therapy) trial\(^1\) (dabigatran 110 or 150 mg twice daily), the ROCKET-AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation)\(^2\) trial (rivaroxaban 20 mg once daily), the ARISTOTLE (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation)\(^3\) trial (apixaban 5 mg twice daily), and the ENGAGE AF TIMI 48 (Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation–Thrombolysis in Myocardial Infarction 48)\(^4\) trial (edoxaban 60 or 30 mg once daily), using dose-adjusted warfarin as standard-of-care control, showed noninferiority or superiority for the efficacy outcome of combined ischemic stroke and systemic embolism in patients with nonvalvular AF. However, the composite outcome of major bleeding does not differ substantially from warfarin.

The exact mechanism of thrombus formation in AF-related strokes, although not yet fully understood, involves the presence of endocardial injury, hypercoagulability, and blood stasis in the atria. The latter seems to play a pivotal role; in fact, the failure of the left atrium to effectively contract results in atrial stretch and dilation, favoring thrombus formation. Approximately 75% of embolic events associated with AF result from atrial thrombosis. A review of autopsy, echocardiographic, and operative reports demonstrate that atrial thrombi can be identified in the left atrial appendage (LAA) in 91% of nonvalvular AF cases and 57% of rheumatic AF cases. AF is associated with a systemic prothrombotic state characterized by endothelial dysfunction and platelet activation. There are several anatomical features and physiological characteristics that explain the pivotal role played by the LAA as a major site of thrombus formation and source of thromboembolic stroke. First, the wall of the LAA has numerous trabeculae (pectinate muscles), forming crypts that can harbor blood clots. These features differentiate the LAA from the left atrium that has a smooth wall. A different embryologic origin explains this different characteristic. Douglas et al\(^2\) described that the LAA originates by the incorporation of the left pulmonary vein in the body of the left atrium. Second, the macroscopic anatomy of the LAA is complex and highly variable, with a long, tubular, and often multilobed body extending over the atrioventricular groove and left ventricular surface. Recently, a correlation between the morphology of the LAA and embolic risk has been described. The LAA ostium is usually oval-shaped and located anterior and inferior to the left superior pulmonary vein.

Third, the LAA is also more distensible than the left atrium itself and can receive a large volume of blood when the pressure in the left atrium is high. Thus, the LAA acts as a decompression chamber of the left atrium. Fourth, a reduction in stroke volume and cardiac output has been described after removal of the LAA. Fifth, anatomically, the LAA lies superior and anterior to the left ventricle in close contact with the left ventricular wall. As a consequence, changes in the left ventricular volume and pressure can be transmitted to the LAA wall, which affects blood flow through the LAA.

Finally, the LAA plays an important physiologic function in regulating intravascular volume through the release of atrial natriuretic factor. Of note, almost 30% of atrial natriuretic factor is stored in the LAA.

Since 1949, surgical LAA exclusion has been performed to reduce stroke risk in cardiac valve surgery in patients with AF, but this procedure is too invasive to be used as a stand-alone operation in patients who do not have any other concurrent indication to undergo cardiac surgery. Percutaneous LAA closure is a relatively new procedure that obviates the need for sternotomy and cardiopulmonary bypass and is an attractive alternative to chronic anticoagulation with VKAs or NOACs in reducing stroke risk in nonvalvular AF. Exclusion of the LAA cavity from the atrium can be achieved with devices that are positioned at the neck of the LAA by either an endovascular or epicardiac approach (Table 1).

This review describes the current technologies used in percutaneous LAA closure (Table 2), as well as a summary of the published trials concerning their efficacy in reducing stroke risk in AF.

**Percutaneous LAA closure: endovascular approach**

The PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) device (Appriva Medical, Inc., Sunnyvale, CA, USA) was the first LAA occlusion device designed; however, as of 2007, it is no longer in production. It consists of a self-expanding nitinol cage covered by an impermeable polymeric membrane. Three rows of anchors along the struts help stabilize the device in the LAA. The diameters of the PLAATO device range between 15 and
Table 1 Characteristics and results of the main clinical trials in left atrial appendage closure, including safety and efficacy

<table>
<thead>
<tr>
<th>Device and study</th>
<th>Patients, n</th>
<th>Follow-up, months</th>
<th>Procedural success, %</th>
<th>Procedural complications, %</th>
<th>Incidence of stroke at follow-up, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Percutaneous Left Atrial Appendage Transcatheter Occlusion</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sievert et al29</td>
<td>15</td>
<td>1</td>
<td>100</td>
<td>6.7% nonfatal hemopericardium</td>
<td>0</td>
</tr>
<tr>
<td>Ostermayer et al20</td>
<td>111</td>
<td>9.8</td>
<td>97.3</td>
<td>0.9% cardiac tamponade, 0.9% femoral artery perforation, 4.5% nonfatal hemopericardium</td>
<td>2.2</td>
</tr>
<tr>
<td>Bayard et al27</td>
<td>291</td>
<td>12</td>
<td>NS</td>
<td>3.4% cardiac tamponade, 0.3% death</td>
<td>3</td>
</tr>
<tr>
<td>Block et al24</td>
<td>64</td>
<td>60</td>
<td>95.3</td>
<td>1.5% cardiac tamponade</td>
<td>3.8</td>
</tr>
<tr>
<td>Park et al25</td>
<td>73</td>
<td>24</td>
<td>97.3</td>
<td>1.4% death caused by device embolization, 1.4% nonfatal hemopericardium, 1.4% periprocedural stroke</td>
<td>0</td>
</tr>
<tr>
<td>Ussia et al26</td>
<td>20</td>
<td>40</td>
<td>90</td>
<td>5% nonfatal hemopericardium</td>
<td>0</td>
</tr>
<tr>
<td>Bayard et al22</td>
<td>180</td>
<td>9.6</td>
<td>90</td>
<td>3.3% nonfatal cardiac tamponade, 0.6% device embolization, 1.1% death</td>
<td>2.3</td>
</tr>
<tr>
<td>Watchman</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sick et al30</td>
<td>75</td>
<td>24</td>
<td>88</td>
<td>2.6% cardiac tamponade, 4% hemopericardium, 2.6% device embolization, 5.3% thrombus formation on device</td>
<td>0</td>
</tr>
<tr>
<td>Holmes et al28</td>
<td>707</td>
<td>18</td>
<td>91</td>
<td>4.9% hemopericardium, 0.7% device embolization, 3.7% thrombus formation on device</td>
<td>2.3</td>
</tr>
<tr>
<td>Amplatzer Cardiac plug</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meier et al30</td>
<td>16</td>
<td>4</td>
<td>93.75</td>
<td>6.25% device embolization, 5% coronary air embolism, 5% esophageal injury resulting from TEE</td>
<td>0</td>
</tr>
<tr>
<td>Lam et al36</td>
<td>20</td>
<td>12</td>
<td>95</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Lopez-Minguez et al37</td>
<td>35</td>
<td>21</td>
<td>97.14</td>
<td>2.8% arteriovenous fistulas, 2.8% gastrointestinal bleed, 14.28% thrombus formation on device</td>
<td>2.8</td>
</tr>
<tr>
<td>Park et al37</td>
<td>137</td>
<td>NS</td>
<td>96</td>
<td>3.6% hemopericardium, 1.4% device embolization</td>
<td>2.2</td>
</tr>
<tr>
<td>Amulet</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Freixa et al32</td>
<td>25</td>
<td>3</td>
<td>96</td>
<td>None reported</td>
<td>0</td>
</tr>
<tr>
<td>LARIAT®</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bartus et al39</td>
<td>13</td>
<td>NS</td>
<td>92.3</td>
<td>None reported</td>
<td>0</td>
</tr>
<tr>
<td>Bartus et al40</td>
<td>89</td>
<td>12</td>
<td>95</td>
<td>3.3% access related</td>
<td>0</td>
</tr>
<tr>
<td>Stone et al41</td>
<td>27</td>
<td>4</td>
<td>92.6</td>
<td>3.7% left atrial appendage perforation, 11.1% pericarditis</td>
<td>3.7</td>
</tr>
</tbody>
</table>

Abbreviations: NS, not stated; TEE, trans esophageal echocardiogram.

35 mm, and it is 20%–40% larger than the LAA ostium. It is deployed through a catheter introduced via the femoral vein and is advanced from the right to the left atrium by transseptal puncture. During the months after the procedure, the device endothelializes with proliferation of a new layer of neointima, starting at the edges of the device. The neointimal growth is continued with the atrial wall and is usually tighter at the border of the implant surface and looser at the center.28 The time span for a complete sealing of the device in the atrial wall is usually around 3 months. However, the amount of time an antithrombotic agent should be administered to avoid thrombotic complications is highly debated in the literature. After PLAATO implantation, lifelong ASA administration is, in general, recommended.

In 2002, Sievert et al29 published a pilot study evaluating the feasibility and safety of the PLAATO device. Fifteen patients underwent a successful procedure, although one patient required a second attempt after sustaining hemopericardium. Subsequent studies on the PLAATO device focused on the effectiveness of percutaneous...
LAA occlusion in preventing strokes. The International Multi-Center Feasibility trial\textsuperscript{30} enrolled 111 patients with contraindication to anticoagulation therapy. The success rate of implantation was 97.3%; reasons for unsuccessful implantation were thrombus in the LAA in one patient, perforation of the femoral artery during femoral puncture in another patient, and cardiac tamponade in the third patient. Pericardial effusion or hemopericardium occurred in 4.5% of patients. During a 9.8 month follow-up, a 65% reduction in stroke rate was observed compared with the expected stroke risk, as calculated using the CHADS\textsubscript{2} score (representing congestive heart failure, hypertension, age, diabetes mellitus, and stroke), the CHADS\textsubscript{2} score is a clinical prediction rule widely used for estimating the risk of stroke in patients with nonvalvular AF. It is worth emphasizing that the authors excluded three transient ischemic attacks (TIAs) from the number of strokes and justify this on the basis that the CHADS\textsubscript{2} score was elaborated to calculate the risk for strokes and not for TIAs.\textsuperscript{31} Residual peridevice leaks were observed not uncommonly by fluoroscopy or echocardiogram, and LAA occlusion was defined as absent, trace, or a mild leak on the basis of these imaging modalities. This is a point of interest that has been the focus of critique not only for the PLAATO device but also for the newer devices as well and will be discussed later on in this review.

Bayard et al\textsuperscript{32} report their experience with the PLAATO device in 180 patients. The LAA closure procedure was successful in 162 (90%) but failed in 18 (10%) patients because of anatomic characteristics of the LAA (14 cases), impossibility of accessing the LAA (2 cases), complications during transseptal puncture (1 case), and device instability (1 case). Two unexplained deaths occurred within 24 hours of the procedure. Six cases of cardiac tamponade were registered, and two required surgical drainage. One PLAATO device embolized requiring retrieval by snaring catheter, and a larger device was successfully implanted in the same procedure. One case of device thrombus documented at 1 month eventually resolved with low-molecular-weight heparin. The observed stroke rate was 2.3%, correlating to a 65% reduction compared with a CHADS\textsubscript{2}-based estimate.

A composite of the International Multi-Center Feasibility trial and the European-only PLAATO Registry Study,\textsuperscript{37} including almost 300 patients, demonstrated a relative reduction of stroke rate of 54% with PLAATO compared with the stroke rate in a historic control group, using the CHADS\textsubscript{2}.\textsuperscript{33} In this registry, thrombus formation was reported in 1% of cases within the first 6 months and was not associated with any neurological events.

Long-term follow-up of the PLAATO device is reported in three trials. Block et al\textsuperscript{34} reported a mean 3.75 year follow-up of 64 patients. The observed annual stroke rate was 3.8%, which correlated with a 42% reduction compared with the CHADS\textsubscript{2}-expected risk. Park et al\textsuperscript{35} reported a 2 year follow-up in 73 patients. The success rate of LAA occlusion was 97.3%, and procedural complications included one death resulting from device embolization, one pericardial effusion, and one periprocedural stroke. During follow-up, no strokes were observed, diverging from an expected incidence of seven events. Finally, Ussia et al\textsuperscript{36} successfully implanted the PLAATO device for LAA occlusion in 18 of 20 patients. One pericardial effusion occurred, requiring pericardiocentesis. No strokes were observed during a 40-month follow-up period.

Nevertheless, financial problems of the manufacturer and a significant rate of adverse events, as mentioned earlier, led to discontinuation of the device in 2006.\textsuperscript{37}

The Watchman LAA System (Figure 1) became available in 2002. Similar to the PLAATO device, it is a nitinol-cage device with a row of fixation barbs around the surface, but it differs from the PLAATO device in that its polymeric membrane is permeable. The Watchman LAA closure device is available in five different sizes, ranging from 21 to 33 mm, and is usually selected 10%-20% larger than the LAA ostium.

### Table 2 Technical characteristics of the devices

<table>
<thead>
<tr>
<th>Device</th>
<th>Deployment</th>
<th>Sizes</th>
<th>Device selection</th>
<th>Anticoagulation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Percutaneous Left Atrial Appendage Transcatheter Occlusion</td>
<td>Endovascular</td>
<td>15–32 mm</td>
<td>20%–40% larger than the left atrial appendage ostium diameter</td>
<td>No</td>
</tr>
<tr>
<td>Watchman</td>
<td>Endovascular</td>
<td>21, 24, 27, and 30 mm</td>
<td>10%–20% larger than the left atrial appendage ostium diameter</td>
<td>Yes (45 days)</td>
</tr>
<tr>
<td>Amplatz cardiac plug</td>
<td>Endovascular</td>
<td>16–30 mm</td>
<td>10%–20% larger than the left atrial appendage orifice</td>
<td>No</td>
</tr>
<tr>
<td>Amulet</td>
<td>Endovascular</td>
<td>16–34 mm</td>
<td>3–6 mm larger than the left atrial appendage ostium</td>
<td>No</td>
</tr>
<tr>
<td>Lariat</td>
<td>Endo-epicardial</td>
<td>W40 × H20 × L70 mm</td>
<td>N/A</td>
<td>No</td>
</tr>
</tbody>
</table>

**Abbreviations**: N/A, not available; W, width; H, height; L, length.
The PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) trial, published in 2009, was a randomized controlled trial that involved the randomization of 707 AF patients with at least one stroke risk factor to the Watchman device versus warfarin in a 2:1 fashion. The device was found to be noninferior to warfarin for the combined end-point of stroke, systemic embolism, and cardiovascular death. The success rate for implantation was 91%, with procedural complications including pericardial effusions requiring intervention in 4.8% and device embolization in 0.6%. Thrombus formation on the device was observed in 3.7% of cases at 6 weeks postprocedure.

Those receiving the device were treated with warfarin for approximately 45 days, followed by clopidogrel for 4.5 months, and then lifelong ASA. Because only 30% of patients had been followed for more than 2 years in the original publication of the PROTECT AF trial, the success of the device could have been attributed in part to the ongoing anticoagulation that was received. However, a recently published 2.3 year (±1.1 years) follow-up study of PROTECT AF confirmed the noninferiority of the Watchman device. There were no statistically significant differences detected in individual comparisons between the two groups; however, the confidence interval was wide (95% confidence interval, 0.36–1.76). The device group exhibited more ischemic strokes, but less cardiovascular death and less hemorrhagic stroke. Of note, all patients in the control group received warfarin (time in therapeutic international normalized ratio range was 66%), with 34% of control patients having had interrupted anticoagulation at some point for various reasons. The primary safety endpoint, which included both procedure-related events (including pericardial effusion requiring intervention of hospitalization, procedure-related stroke, or device embolization) and major bleeding (intracranial bleeding or gastrointestinal bleeding requiring transfusion) was higher in the device group (5.5% per year) than the control group (3.6% per year), for a risk ratio of 1.53 (95% confidence interval, 0.95–2.70). Importantly, patients with a previous history of stroke or TIA appeared to receive sustained benefit from the device that was at least as good as warfarin therapy.

Peridevice leaks with the Watchman device detected by transesophageal echocardiography were common (up to 30% at 12 months), although a recent retrospective analysis of the PROTECT AF trial showed no effect on the effectiveness of the device. LAA closure with the Watchman device also resulted in improved quality of life.

Gangireddy et al estimated the net clinical benefit (NCB) of percutaneous LAA closure in a post hoc analysis of outcomes among 707 AF patients in the PROTECT AF trial and 566 in the Continued Access registry who were undergoing LAA closure with the Watchman device compared with anticoagulation with a VKA. Outcomes were ischemic stroke, intracranial hemorrhage, major bleeding, pericardial effusion, and death. The NCB was calculated as the sum of annualized rates of these outcomes after intervention minus rates when receiving warfarin. The NCB initially favored anticoagulation, but 6–9 months after the procedure, the NCB then favored the device-based intervention, driven mainly by reductions in intracranial hemorrhage and death in patients undergoing LAA closure. Importantly, operator experience significantly affected the safety and efficacy end-points of the intervention: the incidence of procedure-related events was considerably lower in the nonrandomized Continued Access registry that followed the PROTECT AF trial, with the NCB clearly favoring intervention in the registry. As expected, the highest net clinical benefit was observed for patients with high CHADS2 scores.
Sick et al performed 75 Watchman device implantations, of which 66 (88%) were successful. No strokes were observed during a 24-month follow-up. Two cardiac tamponades were reported as well as three pericardial effusions not requiring intervention. Thrombus formation in four patients, in addition to two device embolizations, was reported.

Originally, VKA therapy was required for 45 days after LAA closure with the Watchman device, followed by dual-antiplatelet therapy for up to 6 months, followed by ASA alone. The ASAP Study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology), presented in 2012, was a feasibility study designed to evaluate whether the Watchman device could be used for patients who were unable to take warfarin. In this nonrandomized study enrolling 150 patients with an average CHADS\textsubscript{2} score of 2.8 who had a contraindication to anticoagulation, patients were treated with both ASA and clopidogrel for 6 months after implantation instead of the standard warfarin. During follow-up, three ischemic strokes were observed, corresponding to 1.7 events per 100 patient-years (a 77% reduction in the expected stroke rate based on the CHADS\textsubscript{2} score estimate). In fact, despite not using warfarin, the event rate was lower than in the PROTECT AF study (2.2 strokes per 100 patient-years). These new data permitted the use of the Watchman device in patients with nonvalvular AF and contraindications to VKA therapy.

It should be noted that LAA closure does not eliminate the need of warfarin. An editorial published by Whitlock et al showed that patients undergoing LAA closure still had a considerable incidence of stroke in the randomized and nonrandomized control trials at follow-up. Specifically alluding to the PROTECT AF trial, incidence of strokes at follow up were 50% more in the device group compared with the warfarin group, at 3.0% versus 2.0%. One can argue the need for anticoagulation or antiplatelet therapy added to LAA closure indefinitely.

Last, the PREVAIL (Watchman LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy) study was a randomized controlled trial including 269 patients in the Watchman LAA closure group compared with 138 patients in the warfarin group. Although the study group (Watchman) did not achieve the prespecified criteria for noninferiority at 18 months' follow-up compared with the control group (Warfarin), the overall periprocedural early events were lower than in the PROTECT AF trial, at 2.2% versus 4.9%, respectively. Overall, adverse events in the PREVAIL trial were significantly lower than in the PROTECT AF trial, at 4.2% versus 8.7% ($P=0.004$).

The Amplatzer cardiac plug (ACP; Figures 2 and 3) is a nitinol device. Unlike the PLAATO and Watchman devices, the ACP consists of two parts, the lobe and the disc, which are connected by a central waist. Twelve stabilizing wires are equally displaced around the main disc and contribute to device retention and stabilization inside the LAA. The sizes of the lobe range from 16 to 30 mm, and it is designed to hug the inner wall of the LAA. The lobe enters into the LAA neck with a depth of 10 mm or more, anchoring the device, whereas the disc covers the LAA orifice, thereby occluding it. After the procedure, 1 month of double antiplatelet...
therapy is recommended, followed by 5 months of ASA. The Initial European Experience by Park et al\textsuperscript{47} is a retrospective analysis of 143 patients who received the ACP device. Six patients were excluded because of difficult LAA anatomy or thrombus, and 137 procedures were attempted, of which 133 were successful (96%). Ten patients (7%) experienced complications: three periprocedural strokes, two device embolizations, five cardiac tamponades requiring pericardiocentesis, and four pericardial effusions with spontaneous resolution. Two transient episodes of myocardial ischemia resulting from air embolism were reported. The study showed the feasibility of LAA closure with the ACP device, as well as its relatively low rate of complications.

Lam et al\textsuperscript{48} reported 20 cases, of whom 19 (95%) underwent successful implantation of the ACP device. They also reported one episode of transient myocardial ischemia and one esophageal lesion resulting from transesophageal echocardiography. No strokes were observed during a 12.7 month follow-up period compared with an estimated risk of 5.3%.

López-Minguez et al\textsuperscript{49} recently published a trial of 35 patients treated with the ACP device. The implantation was successful in 97.14% of patients. No cardiac complications were observed, one femoral arteriovenous fistula was reported, and one severe gastrointestinal bleeding was observed, at which point clopidogrel was stopped and ASA alone was continued. Thrombus formation on the ACP surface was documented in five cases (14.28%), and in four of them, enoxaparin was administered, with eventual thrombus resolution. During a 21-month follow-up period, only one TIA was observed in the patient who exhibited thrombus formation and did not receive enoxaparin. A transesophageal echocardiography performed in this patient showed three minor leaks at the border of the device.

Urena et al\textsuperscript{50} published a trial on 52 patients treated with the ACP device who demonstrated a contraindication to warfarin. The procedural success rate was 98.1%. A single embolization was recorded, but the device was retrieved percutaneously. One patient experienced a TIA 24 hours after the procedure despite no visualized intracardiac thrombus and evidence of complete LAA sealing by transesophageal echocardiography. During a mean 20 months of follow-up, a lacunar stroke and second TIA were reported. Nevertheless, the number of strokes, thromboembolic events, and major bleeding events were significantly lower than expected based on CHA\textsubscript{2}-DS\textsubscript{2}-VAsc (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus, prior stroke or TIA or thromboembolism, vascular disease, age 65 to 74 years, sex) and HAS-BLED (hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile international normalized ratio, elderly, drugs/alcohol concomitantly) score estimates. Perdevice residual leaks as assessed using transesophageal echo were observed in 16.2% of cases at 6 months; however, none of these patients experienced a stroke or TIA. Leaks were significantly associated with low ejection fractions, suggesting modification in LAA dimensions through remodeling can cause incomplete sealing. The lower rate of leaks using the ACP device as compared with that observed with the Watchman device is likely a result of the peculiar form of this device, which allows the disc to cover the LAA ostium, whereas the closure in the Watchman device is performed by positioning the device inside the LAA neck.

A recent systematic review\textsuperscript{51} evaluated the success and adverse event rates of percutaneous LAA device occlusion by combining 14 trials (1,737 patients). No distinction was made among individual devices despite combining trials, which evaluated the PLAATO, Watchman, or ACP devices. Overall, the authors concluded that LAA closure was successfully performed in 93% of cases with a 1.1% periprocedural mortality. Systemic embolism occurred in 1.6%, cardiac perforation in 0.9%, pericardial effusion and cardiac tamponade in 4%, and device embolization in 0.7%. Major bleeding occurred in 0.7% of patients. When the observed stroke incidence of eight trials was compared with the estimated stroke risk, as predicted from the CHADS\textsubscript{2} score, an overall risk reduction of 1.9%–8.6% to 0%–3.8% was observed.

The newest Amplatzer Amulet (ACP-2) is the evolution of the original ACP device, a dedicated device for percutaneous LAA occlusion (Figure 4). The main design of the first

![Figure 4 Amplatzer Amulet.](https://www.dovepress.com/)

**Notes:** Note the increased length of the distal lobe and the diameter of the proximal disc. Note the amulet has the screw inside while the ACP has a screw through it.
generation ACP-1 is maintained, although several features were modified to improve feasibility of implantation procedure and orifice sealing: the stabilizing wires are stiffer and the number is increased from six to ten pairs, larger sizes are available (31 and 34 mm), the length of the distal lobe is increased by 2–3 mm, and the diameter of the proximal disc was increased by 5.5–8 mm. Freixa et al reported successful implantation in 24 of 25 patients with no periprocedural complications and no strokes at 3 months, suggesting feasibility and safety.

**Percutaneous LAA closure: epicardial approach**

Although most of the experience with LAA occlusion devices has been with endocardial devices, isolation of the LAA using an epicardial approach has more recently emerged as an attempt to simulate LAA closure with suture ligation during cardiac surgery. LAA occlusion with a percutaneous suture ligation method has been shown to be feasible for acute closure of the LAA and has been shown to result in LAA necrosis and atrophy. Endocardial suture ligation during cardiac surgery has been demonstrated to be incomplete in 10%–30% of patients, thus predisposing the patient to thromboembolic events. Potential reasons for incomplete closure include that the procedure is performed when the heart is in a flaccid state during cardiopulmonary bypass, that the access for suturing may be difficult, and that the success of LAA closure cannot be determined until the patient resumes cardiopulmonary bypass. These reasons may be mitigated by using a percutaneous epicardial approach without the need for cardiopulmonary bypass. Further, LAA isolation has been reported as a successful therapy for LAA tachycardias through electrical isolation and could allow elimination of focal LAA triggers that potentiate atrial tachycardias and AF. In addition, they offer further benefit because epicardial devices negate the need to implant a permanent endovascular device, as with the endocardial approach. The disadvantage with the epicardial approach is the need for pericardial access; patients who have had previous cardiac surgery are therefore not candidates for an epicardial device. There is also a percentage of the population that is not eligible for an epicardial occlusion device because of the unsuitable anatomy of the LAA.

At the present time, two device systems are available for use using an epicardial approach for LAA exclusion. The Aegis System is a percutaneous device that is positioned around the LAA to perform ligation. The system consists of an appendage grabber and a ligator. The most interesting aspect of this procedure is represented by an electrocardiogram-guided research of the LAA by the two electrodes mounted at the extremity of the grabber. Once the appendage is identified, a transseophageal echocardiogram or intracardiac ultrasound can be used to confirm the correct capture of the appendage. The second step of the procedure consists of ligating the appendage through a wire loop advanced over the grabber. In cases in which the appendage has multiple lobes, ligation can be performed in different positions. Results of this new approach are encouraging.

The LARIAT device is an LAA exclusion device that consists of a pretied suture enclosed in on a closed snare and that employs a hybrid endocardial-epicardial approach. Through a transseptal puncture, a magnetic probe is placed inside the LAA. Another magnetic probe is introduced in the pericardial space via a percutaneous epicardial approach. Over this endocardial-epicardial magnetic wire bridge, a LARIAT suture is inserted over the wire in the pericardial space to find the LAA and snare it. There is no requirement for anticoagulation or antplatelet use after the procedure. Bartus et al first performed successful LAA exclusion using the LARIAT device in 13 patients: eleven with a closed-chest procedure and two during open-chest valvular cardiac surgery. A subsequent nonrandomized, single-center study evaluated a total of 119 patients for LAA ligation with the LARIAT device. Because of the thrombi within the LAA or unsuitable anatomy, only 89 patients (75%) underwent LAA ligation. A 95% success rate was reported, as assessed by transseophageal echocardiography. There were three procedure-related complications (two of which were related to pericardial access and one to transseptal access). There were no device complications. There were no embolic strokes seen in the year of follow-up. Two deaths occurred more than 6 months after the procedure that were not related to the LARIAT device. Another small study published by Stone et al showed a success rate of 92.6% via a percutaneous LAA ligation approach with the SentreHeart LARIAT snare device. All 27 patients were followed-up to 4 months. Periprocedural complications included one patient with LAA perforation, three patients developing pericarditis, and one patient having a stroke. On follow-up, stroke rate was 3.3%.

In 2014, Han et al published a study on the effect of LAA ligation with the LARIAT device on LAA electrical activity. The trial included 68 patients with 100% procedural implantation success. Ninety-four percent of the patients had a reduction in the LAA voltage after the closure of the snare, with 33% of the patients having complete elimination of LAA voltage with the initial tightening of the suture. These preliminary results are interesting in the context in which LAA occlusion with this particular device may help decrease recurrence of atrial fibrillation in this patient population.
Considering all these studies, one can state that the LAA occlusion procedure can be performed with the LARIAT® device with high success rates and acceptably low access complications and adverse events, except pericarditis, which is reported in all studies using that device. Because this technique requires an epicardial approach, further research on device/suture material or adjuvant anti-inflammatory therapy that may reduce risk for pericarditis is required to improve procedural safety.

Risks from the catheter-based access of LAA occlusion also have their limitations. As mentioned in Table 1, many procedural complications have been noted with every device, including the PLAATO, Watchman, ACP, and LARIAT® devices. It is encouraging to see, for example, in the PREVAIL study, that as this technique evolves, the rate of complications decreases. Nevertheless, its adverse outcomes are still nonnegligible.

Current state of percutaneous LAA closure and future directions
LAA closure is an intervention of increasing interest, in particular for patients with either contraindications to anticoagulation therapy, embolic events while receiving anticoagulation therapy, or intolerance to anticoagulants. Published trials demonstrate high overall success rates with favorable safety profiles compared with VKAs. LAA device closure has been recently been introduced into the 2012 focused update of the European Society of Cardiology as well as the 2014 American College of Cardiology/American Heart Association/Heart Rhythm Society guidelines for the management of AF in patients at high risk for embolic stroke and contraindication to anticoagulants. Published trials demonstrate high overall success rates at long-term therapy with an oral anticoagulant, for which it has been given a class IIb recommendation for both. At this time, no evidence supports the systematic closure of LAA in patients with no contraindications to oral anticoagulants. Moreover, the advent of the NOAC will have a deep effect on the management of patients with nonvalvular AF and may further limit the indications for percutaneous LAA closure. Notably, no trials have been designed to compare NOACs with LAA closure or to evaluate the use of NOACs as adjunctive therapy in patients undergoing LAA closure. Furthermore, LAA occlusion with current devices does not obviate the need for long-term antithrombotic therapy with aspirin.

Percutaneous LAA closure can be associated with several procedural complications such as major bleeding, pericardial effusion, pericarditis, cardiac perforation, and air embolism. Moreover, the differences in LAA anatomy can increase the complexity of the procedure, posing challenges to accessing the LAA and sealing the LAA orifice.

Several device-related aspects still limit this approach, such as the high rate of incomplete LAA closure reported at long-term follow-up with transesophageal echocardiography and the occurrence of device embolization and migration. The Coherex Wave-crest is a new device for LAA closure furnished with anchoring points and the possibility of assessing device stability through a distal injection port during the procedure. Preliminary animal studies report durable LAA occlusion and an improved biocompatibility.

Future refinements of LAA occlusion technology are expected to improve the feasibility of the procedure. The device design and coating should aim to overcome the limitations of incomplete LAA orifice sealing and device dislodgement. In contrast, acute procedural complications have been shown to be influenced by a learning curve, and operator experience deeply affects outcomes of the procedure.

The evolution and application of LAA closure in clinical practice will be related to an extensive knowledge of physiopathology of LAA and its effect on AF. Its has been shown that LAA is an alternative site for AF trigger, and as stated earlier, LAA closure has been linked to a reduction in recurrence of paroxysmal AF episodes. Moreover, hemodynamic consequences of LAA exclusion such as reduction in stroke volume and cardiac output have been amply documented.

The occurrence of LAA thrombus increases in patients with AF and severe heart disease. The reduced ejection fraction and increased heart rate are a major determinant of the blood flow through the LAA and blood clot formation. Indications for LAA closure will depend on further studies to define subgroups of patients achieving maximal benefit from LAA exclusion.

Disclosure
VE is a recipient of a Clinician Scientist Award from the Canadian Institutes of Health Research. AT is proctor for St Jude Medical. PD is proctor for Gore & Associates, St Jude Medical and Boston Scientific. The other authors have no conflicts of interest in this work.

References


